Divan A. Burger

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt et al. · The Lancet · 2015 · 248 citations

Pulmonary Tuberculosis, Phase 2B, Tuberculosis Prevention +9

Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline

Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 200 citations

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Conor Tweed, Rodney Dawson, Divan A. Burger et al. · The Lancet Respiratory Medicine · 2019 · 143 citations · Full text

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

Patrick Phillips, Carl M. Mendel, Divan A. Burger et al. · BMC Medicine · 2016 · 75 citations · Full text

Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia

Reinout van Crevel, Bachti Alisjahbana, F Borst et al. · The International Journal of Tuberculosis and Lung Disease · 2002 · 72 citations